NCT06304597View on ClinicalTrials.gov

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

June 1, 2025

Conditions

Locally Advanced Rectal Carcinoma

Interventions

DRUG

Imfinzi

Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)

DRUG

Opdivo

Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors

lead

University Medical Center Groningen

OTHER

NCT06304597 - Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy | Biotech Hunter | Biotech Hunter